Introduction {#s1}
============

At high intensities of exercise in normoxia, above the respiratory compensation threshold (RC), hyperventilation-induced hypocapnia constricts the cerebral vessels, thereby reducing cerebral blood flow (CBF) and lowering cerebral oxygen delivery [@pone.0081130-Madsen1]--[@pone.0081130-Olin1]. In conditions of hypoxia, in spite of hypoxic vasodilation, the hypocapnia-induced limitation of CBF at high exercise intensities is further aggravated due to a greater ventilatory drive. Such a limitation of CBF might lead to inadequate cerebral O~2~ delivery, triggering early motor drive withdrawal, thus limiting exercise performance in hypoxia [@pone.0081130-Amann1], [@pone.0081130-Nybo1]. In support, several studies found a relationship between performance and cerebral deoxygenation in hypoxia using various exercise modes such as repeated sprints [@pone.0081130-Smith1], incremental exercise [@pone.0081130-Subudhi1], [@pone.0081130-Peltonen1], and static maximal muscle contraction to exhaustion [@pone.0081130-Rasmussen1]--[@pone.0081130-Goodall1]. Similarly, under normoxic conditions, exacerbation of exercise induced cerebral deoxygenation, by administering a non-selective beta-blocker, is accompanied by impaired maximal exercise performance [@pone.0081130-Seifert1]. This has led to the hypothesis that an exaggerated hyperventilation-induced hypocapnia and subsequent reduction in CBF during heavy exercise might account, in part, for the impaired performance in hypoxia.

Recently, studies have assessed the effect of preventing the normal drop in end-tidal PCO~2~ on CBF and exercise performance in normoxia [@pone.0081130-Fan1] and hypoxia [@pone.0081130-Subudhi2], [@pone.0081130-Siebenmann1]. Subudhi et al., [@pone.0081130-Subudhi2] reported impaired exercise capacity at 1,600 m and 4,875 m (hypobaric chamber) when they clamped end-tidal PCO~2~ (PETCO~2~) either: 1) at 50 mmHg throughout incremental exercise or 2): at 40 mmHg from ∼75% maximal work rate until exhaustion. Siebenmann et al., [@pone.0081130-Siebenmann1] completed those observations by investigating, at a more moderate altitude (3,454 m), the impact of clamping PETCO~2~ at 40 mmHg, on performance. Both of these studies found clamping PETCO~2~ increased MCAv and attenuated the decrease in cerebral oxygenation, but slightly decreased peak power output without affecting maximal oxygen uptake. Subudhi et al., [@pone.0081130-Subudhi2] found ventilation (E) was elevated (by ∼50 L/min) during submaximal exercise intensities (37 and 75% of maximal hypoxic work rate) with PETCO~2~ clamping, compared to without added CO~2~. As such, they attributed the reduced performance with CO~2~ clamping to earlier functional limitation by the respiratory system associated with CO~2~ breathing. Since these studies were carried out in subjects living at moderate altitude [@pone.0081130-Subudhi2] and in low altitude residents following a day spent at high altitude[@pone.0081130-Siebenmann1], respectively, both conditions accompanied by enhanced cerebrovascular and ventilatory responsiveness to CO~2~ [@pone.0081130-Fan2], [@pone.0081130-Mathew1], the acute effect of augmented FICO~2~ and hypoxia on CBF during exercise in an altitude-naïve population remained unclear.

For climbing 8,000 m peaks, a strong ventilatory response at altitude is believed to be a factor for success [@pone.0081130-Schoene1], but increases the risk of brain damage because of excessive hyperventilation-induced cerebral hypoxemia [@pone.0081130-Hornbein1]. By contrast, Bernardi et al., [@pone.0081130-Bernardi1] found that acclimatized elite climbers with a smaller ventilatory response to hypoxia at 5,200 m were more successful climbing to extreme altitude (Everest and K2), perhaps due to a greater ventilatory reserve (difference between maximal voluntary ventilation and effective minute ventilation) at these altitudes. Therefore, the effect of augmenting FICO~2~ on ventilation during exercise is of interest, particularly in the presence of enhanced ventilatory drive associated with hypoxia.

We tested the hypotheses that, in non-altitude acclimatized subjects, increasing PETCO~2~ during incremental exercise in normobaric hypoxia would: i) further augment CBF during exercise in hypoxia and improve exercise capacity; and ii) exacerbate the increase in ventilation at sub-maximal exercise intensities but not at maximal effort.

Methods {#s2}
=======

Ethics {#s2a}
------

The study was approved by the Research Ethical Committee of the University Hospitals of Geneva and conformed to the standards set by the Declaration of Helsinki. All subjects were informed regarding the procedures of this study, and informed signed consent was given prior to participation.

Subjects {#s2b}
--------

Ten healthy male subjects with a mean age of 24±3 yr (mean ± SD), a body mass index of 22.7±2.4 kg/m^2^ and O~2~max of 58.3±10.5 ml/min/kg participated in this study. Subjects were non-smokers, had no previous history of cardiovascular, cerebrovascular, or respiratory disease and were not taking any medication. All the subjects were residents of Geneva, Switzerland (∼400 m) and partook in regular exercise (3--6 h per week); none were acclimatized to altitude (i.e., they had not travelled to altitudes \>1,000 m in the past 2 months).

Experimental design {#s2c}
-------------------

The subjects visited the laboratory on five occasions. After a full familiarization with the experimental procedures outlined below (visit one), subjects underwent four experimental exercise trials in a randomized, single-blind and balanced fashion (to prevent order effects), with a 3-day washout period between each experimental session, consisting of the following conditions: i) control normoxia (ambient air, 389 m); ii) augmented FICO~2~ in normoxia; iii) control hypoxia (normobaric simulated altitude, 5,000 m); and iv) augmented FICO~2~ in hypoxia. Before each experimental session, the subjects were asked to abstain from caffeine for 12 h and heavy exercise, and from alcohol for 24 h. Each experimental testing session comprised 20 min instrumentation followed by a 4 min resting baseline collection with the subject breathing room-air and seated on an electronically braked cycle ergometer (Ergoselect 100, Ergoline GmbH, Bitz, Germany). During the hypoxia and augmented FICO~2~ trials, the subjects were then switched to a gas mixing system (described below), breathing the respective gas mixtures for an additional 4 min resting baseline (condition baseline) prior to the incremental cycling test.

Exercise test {#s2d}
-------------

The subjects were instructed to begin cycling at 0 watts at a pedaling rate of 70 rpm. The work rate was increased by 0.5 watts every second (30 W/min) thereafter until the subject reached voluntary exhaustion. Throughout each experimental session, the subjects wore a nose-clip and breathed through a mouthpiece attached to a low resistance one-way non-rebreathing valve (Hans-Rudolph 2700, Kansas City, USA). The hypoxia and augmented FICO~2~ were achieved using a modified gas mixing system (Altitrainer, SMTec, Nyon, Switzerland), which has been previously described in detail [@pone.0081130-Fan1]. In brief, additional CO~2~ was bled into the inspired gas mixture under constant feedback of on-screen PETCO~2~ and FICO~2~ was constantly adapted as to keep PETCO~2~ to a target value of approximately 45 mmHg during both normoxia and hypoxia. The FIO~2~ was held constant at either 0.21 (normoxia, ambient air) or 0.10 (hypoxia). The subjects breathed through the same circuit in all four conditions and were kept unaware to what gas mixture they were breathing and were naive to the rationale of the study. For each subject the experiments were carried out at the same time of day under consistent laboratory conditions (temperature 22.3±0.5°C, humidity 27±7%, barometric pressure 725±4 mmHg).

Measurements {#s2e}
------------

### Respiratory variables {#s2e1}

Gas exchange was monitored on a breath-by-breath basis (Medgraphics CPX, Loma Linda, USA) measuring flow at the mouth with a Pitot tube and the fractions of inspired and expired O~2~ and CO~2~ with fast responding gas analyzers (infrared and paramagnetic) integrated in the system. Ventilation (E) was derived from the flow signal and expressed in body temperature and pressure saturated (BTPS) and L/min, respectively. The partial pressure of end-tidal O~2~ (PETO~2~), CO~2~ (PETCO~2~), O~2~ consumption (O~2~) and CO~2~ production (CO~2~) were calculated by the gas analysis system. Prior to each experimental session the system was calibrated using a 3-L syringe (M9474, Medikro Oy, Finland) and precision gas mixtures of known O~2~ and CO~2~ concentrations.

### Cerebrovascular and cardiovascular variables {#s2e2}

Bilateral middle cerebral artery blood flow velocities (MCAv: as index of CBF) were measured in the middle cerebral arteries using a 2-MHz pulsed Doppler ultrasound system (ST3, Spencer technology, Seattle, USA). The Doppler ultrasound probes were positioned over the temporal windows and held firmly in place with an adjustable headband (Marc 600 Headframe, Spencer technology, Seattle, USA). The signals were at depths ranging from 43 to 54 mm. Signal quality was optimized and an M-mode screen shot was recorded to facilitate subsequent probe placements. In our hands, day-to-day reproducibility of MCAv has a coefficient of variation of \<10%. The bilateral MCAv were averaged to represent an index of global CBF during rest and exercise. Heart rate was measured using a thoracic belt and recorded directly onto a PC via a wireless receiver pod (PC-POD, Suunto, Vantaa, Finland). Peripheral O~2~ saturation (SpO~2~) was measured from the right ear lobe using pulse oximetry (Satlite, Datex, Helsinki, Finland, and ML320 Oximeter Pod, ADInstruments, Bella Vista, Australia). Blood pressure was measured with an automated arm sphygmomanometer (Ergoselect 100, Ergoline GmbH, Bitz, Germany).

### Perceived exertion {#s2e3}

During exercise, the subjects were asked to score their perceived exercise exertion on the 0--10 Borg scale every minute [@pone.0081130-Borg1].

Data and statistical analysis {#s2f}
-----------------------------

### Respiratory compensation threshold and ventilatory response to exercise {#s2f1}

The respiratory compensation threshold (RC) was obtained using the v-slope method previously described by Beaver et al., [@pone.0081130-Beaver1]. The assessment of the ventilatory response to exercise (i.e., the slope of E rise during exercise: E-slope to power output) has been previously described [@pone.0081130-Babb1], [@pone.0081130-Babb2]. In brief, breath-by-breath E points were plotted against mechanical power output and a least squares regression was used to determine the E-slope to exercise above and below RC.

### Statistical analysis {#s2f2}

Resting values were obtained by averaging the data obtained in the last two minutes of the four minutes resting periods just prior to exercise. For the incremental exercise, we took the last 20 sec of every 10% increase in exercise intensity until exhaustion (100%). We then averaged all of the 20 sec segments of the data to obtain a *single mean* value for each variable during all four experimental conditions. The effects of hypoxia and augmenting FICO~2~ on cardiorespiratory and cerebrovascular responses at rest were assessed using two-way repeated-measures ANOVA with α-level of P\<0.05 (IBM SPSS Statistics version 21.0, IBM Corporation, Armonk, USA). Likewise, two-way repeated measure ANOVA was used to assess the effects of hypoxia and augmenting FICO~2~ on these variables during incremental exercise. For significant interactions between hypoxia and augmenting FICO~2~, four pairwise comparisons (Bonferroni corrected) were performed to isolate the effect of hypoxia and augmenting FICO~2~ on the dependent measures within subjects with a α-level of 0.0125, indicated where appropriate with the superscript ^B^. Trends were considered when P\<0.10. All data are reported as means ± SD.

Results {#s3}
=======

All ten subjects completed the experimental protocol. Due to poor gas exchange traces, one subject had to repeat the augmented FICO~2~ in hypoxia trial. Two subjects had to repeat their control normoxia trials, as they initially did not maintain a pedaling rate of 70 rpm during high intensity exercise. One subject reported respiratory dyspnea during exercise in augmented FICO~2~, in hypoxia, while another reported a mild headache lasting 20 min following the control hypoxia trial. No other subjects reported any side effects such as headache or dyspnea following the experiments. Due to poor blood pressure signals during exercise, we were unable to carry out repeated-measures ANOVA analysis on the MAP data during exercise.

Resting variables ([Table 1](#pone-0081130-t001){ref-type="table"}) {#s3a}
-------------------------------------------------------------------

*MCAv*: Hypoxia had no effect on resting MCAv (hypoxia: P = 0.790 vs. normoxia), while augmenting FICO~2~ elevated MCAv by 25±21% during both normoxic and hypoxic conditions (CO~2~: P = 0.001, interaction: P = 0.681).

### Ventilatory variables {#s3a1}

Resting PETCO~2~ was lower with hypoxia (hypoxia: P = 0.001), while it was higher with augmented FICO~2~ (CO~2~: P\<0.001, interaction: P = 0.224). There was an interaction between the effects of hypoxia and augmenting FICO~2~ on resting PETO~2~ (interaction: P = 0.004). Post-hoc analysis shows that PETO~2~ was lowered with hypoxia during both control and augmented FICO~2~ conditions (P\<0.001^B^ vs. normoxia for both), while augmenting FICO~2~ elevated resting PETCO~2~ by a greater extent in normoxia (by 20±5 mm Hg, P\<0.001^B^ vs. control normoxia) compared to in hypoxia (by 10±4 mm Hg, P\<0.001^B^ vs. control hypoxia). Resting E was elevated by hypoxia (P = 0.008 vs. normoxia) and augmented FICO~2~ (CO~2~: P\<0.001, interaction: P = 0.848). There was an interaction between the effect of hypoxia and augmenting FICO~2~ on CO~2~ (interaction: P = 0.003). Post-hoc t-tests showed that hypoxia elevated CO~2~ during control (P\<0.001^B^ vs. control normoxia) but not during augmented FICO~2~ (P = 0.832^B^ vs. augmented FICO~2~ in normoxia). Accordingly, CO~2~ appeared to be lower with augmented FICO~2~ in hypoxia (P\<0.001^B^ vs. control hypoxia) but not in normoxia (P = 0.131^B^ vs. control normoxia). No differences were observed in O~2~ with either hypoxia or augmented FICO~2~ (main effects: P = 0.217 & P = 0.127, respectively, interaction: P = 0.575).

### Cardiovascular variables {#s3a2}

Hypoxia elevated resting HR (hypoxia: P\<0.001 vs. normoxia); there was a slight but non-significant tendency for augmenting FICO~2~ to attenuate this increase in HR (CO~2~: P = 0.886, interaction: P = 0.059). The effect of hypoxia and augmented FICO~2~ on resting SpO~2~ interacted with each other (interaction: P = 0.004). Specifically, post-hoc analysis found SpO~2~ to be lower with hypoxia during both control and augmented FICO~2~ conditions (P\<0.001^B^ vs. normoxia for both). Meanwhile, augmenting FICO~2~ selectively elevated resting SpO~2~ in hypoxia (P\<0.001^B^ vs. control hypoxia), but not in normoxia (P = 0.615^B^ vs. control normoxia). No changes were observed in resting MAP with either hypoxia or augmenting FICO~2~ (main effects: P = 0.809 and P = 0.123, respectively, interaction: P = 0.370).

Exercise {#s3b}
--------

### Performance {#s3b1}

Hypoxia lowered maximal exercise capacity by 26% (251±15 W vs. 338±21 W, hypoxia vs. normoxia, hypoxia: P = 0.001), whereas there was a tendency for maximal exercise capacity to be lowered with augmented FICO~2~ (CO~2~: P = 0.091, interaction: P = 0.397). Specifically, maximal exercise capacity tended to be lower by 4% in normoxia (332±66 W vs. 345±66 W, augmented FICO~2~ vs. control, P = 0.052^B^), while no trend was observed in hypoxia (248±48 W vs. 256±48 W, P = 0.252^B^).

### Ventilatory variables ([Fig. 1A, 1B](#pone-0081130-g001){ref-type="fig"} & [2A--D](#pone-0081130-g002){ref-type="fig"}) {#s3b2}

During incremental exercise, the effect of augmenting FICO~2~ on PETCO~2~ was greater in hypoxia compared to normoxia (interaction: P\<0.001). Post-hoc analysis revealed that throughout exercise, hypoxia lowered PETCO~2~ during control by a greater extent than during augmented FICO~2~ (10±3 mmHg vs. 5±3 mmHg, P\<0.001^B^ vs. normoxia for both). Meanwhile, augmenting FICO~2~ elevated PETCO~2~ by a lesser extent in normoxia compared to in hypoxia (8±3 mmHg vs. 14±3 mmHg, P\<0.001^B^ vs. control for both). In contrast, hypoxia blunted the effect of augmenting FICO~2~ on PETO~2~ (interaction: P\<0.001). Post-hoc comparisons found hypoxia lowered PETO~2~ by 49±2 mmHg during control and by 54±4 mmHg during augmented FICO~2~ conditions (P\<0.001^B^ vs. normoxia for both). Furthermore, augmenting FICO~2~ increased PETO~2~ by 15±3 mmHg in normoxia and by 10±3 mmHg in hypoxia (P\<0.001^B^ vs. control for both).

During incremental exercise, both hypoxia and augmenting FICO~2~ elevated E (main effect: P\<0.001 for both, interaction: P = 0.188). At exhaustion, E reached 74±12% of estimated maximal voluntary ventilation (MVV) in normoxia and 69±11% in hypoxia [@pone.0081130-Kory1].

### MCAv ([Fig. 1C](#pone-0081130-g001){ref-type="fig"}, [2E & 2F](#pone-0081130-g002){ref-type="fig"}) {#s3b3}

During incremental exercise, there was a significant interaction between the effect of hypoxia and augmenting FICO~2~ (interaction: P = 0.010). Post-hoc analysis revealed that hypoxia elevated MCAv during control (P = 0.002^B^ vs. control normoxia), but not during augmented FICO~2~ condition (P = 0.429^B^ vs. augmented FICO~2~ in normoxia). Meanwhile, augmenting FICO~2~ selectively elevated MCAv during incremental exercise in normoxia (P\<0.001^B^ vs. control normoxia), but not in hypoxia (P = 0.145^B^ vs. control hypoxia).

### Oxygen saturation ([Fig. 1D](#pone-0081130-g001){ref-type="fig"}, [2G & 2H](#pone-0081130-g002){ref-type="fig"}) {#s3b4}

The effect of augmenting FICO~2~ on SpO~2~ during exercise was enhanced in hypoxia (interaction: P\<0.001). As such, post-hoc analysis showed that hypoxia lowered SpO~2~ by 26±6% during control condition (P\<0.001^B^ vs. control normoxia) and by 15±6% during augmented FICO~2~ condition (P\<0.001^B^ vs. augmented FICO~2~ in normoxia). Meanwhile, augmenting FICO~2~ elevated SpO~2~ by 12±5% in hypoxia (P\<0.001^B^ vs. control hypoxia), but not in normoxia (P = 0.615^B^ vs. control normoxia).

### Metabolism ([Fig. 1E, 1F](#pone-0081130-g001){ref-type="fig"} & [3A--D](#pone-0081130-g003){ref-type="fig"}) {#s3b5}

Hypoxia lowered both O~2~ and CO~2~ throughout exercise (hypoxia: P\<0.001 vs. normoxia for both), while augmented FICO~2~ had no effect on these variables (CO~2~: P = 0.628 & P = 0.544, respectively, interaction: P = 0.954 & P = 0.304).

### Cardiovascular variables ([Fig. 1G](#pone-0081130-g001){ref-type="fig"}, [3E & 3F](#pone-0081130-g003){ref-type="fig"}) {#s3b6}

During exercise, the effect of hypoxia on HR was offset by the effect of augmenting FICO~2~ (interaction: P = 0.003). Accordingly, post-hoc t-tests found HR to be higher with hypoxia during control (P = 0.001^B^ vs. control normoxia), but not during the augmented FICO~2~ (P = 0.360^B^ vs. augmented FICO~2~ in normoxia). There were trends for augmenting FICO~2~ to elevate HR during exercise in normoxia (P = 0.075^B^ vs. control normoxia) and lower HR in hypoxia (P = 0.019^B^ vs. control hypoxia).

### Rate of perceived exertion ([Fig. 1H](#pone-0081130-g001){ref-type="fig"}, [3G & 3H](#pone-0081130-g003){ref-type="fig"}) {#s3b7}

There was an interaction between effects of hypoxia and augmenting FICO~2~ on RPE (interaction: P = 0.045). As a result, a post-hoc t-tests found a tendency for RPE to be elevated with augmented FICO~2~ in normoxia (P = 0.038^B^ vs. control normoxia), but not in hypoxia (P = 0.598^B^ vs. control hypoxia). Hypoxia had no effect on RPE during control or augmenting FICO~2~ (P = 0.735^B^ & P = 0.180^B^ vs. normoxia, respectively).

### RC and E-slope to exercise ([Fig. 4](#pone-0081130-g004){ref-type="fig"} & [5](#pone-0081130-g005){ref-type="fig"}) {#s3b8}

During exercise, the onset of RC occurred at lower power output in hypoxia compared to in normoxia (by 86±36 W, Hypoxia: P\<0.001). Likewise, the onset of RC occurred at lower power output with augmenting FICO~2~ compared to control conditions (CO~2~: P = 0.015; interaction: P = 0.176). Meanwhile, there was an interaction between the effect of hypoxia and augmenting FICO~2~ on E at RC (interaction: P = 0.021). Post-hoc analysis revealed that hypoxia tended to elevate E at RC under the augmented FICO~2~ condition (P = 0.027^B^ vs. augmented FICO~2~ in normoxia), but not during the control condition (P = 0.112^B^ vs. control normoxia). Augmenting FICO~2~ selectively increased E at RC in hypoxia (by 23.95±21.70 L/min, P = 0.007^B^ vs. control hypoxia), but not in normoxia (P = 0.847^B^ vs. control normoxia). The effect of hypoxia and augmenting FICO~2~ interacted with each other on the E-slope to exercise (the slope of E rise against power) below RC (interaction: P = 0.043). As such, hypoxia elevated the E slope to exercise below RC during both control (by 30±13%, P\<0.001^B^ vs. control normoxia) and augmented FICO~2~ condition (by 93±78%, P = 0.001^B^ vs. augmented FICO~2~ in normoxia). Augmenting FICO~2~ lowered the E slope below RC during normoxia (by 27±14%, P = 0.001^B^ vs. control normoxia), but not during hypoxia (P = 0.786^B^ vs. control hypoxia). In contrast, no differences were observed in the E slope to exercise above RC with either hypoxia or augmenting FICO~2~ (hypoxia: P = 0.256, CO~2~: P = 0.155, interaction: P = 0.585).

Discussion {#s4}
==========

Augmenting FICO~2~ elevated CBF during incremental exercise in normoxia, but, unexpectedly, it did not during hypoxia. Furthermore, we found no improvement in exercise capacity with augmented FICO~2~ during either normoxia or hypoxia. While the roles of hypercapnia and hypoxia in the regulation of CBF during rest have been extensively studied, their effects on cerebrovascular control during exercise are less well documented \[see [@pone.0081130-Ogoh1] for review\]. During exercise, studies have found enhanced CBF response to hypercapnia [@pone.0081130-Rasmussen2], while the CBF response to hypocapnia remained unchanged [@pone.0081130-Ogoh2]. During incremental exercise, we observed higher MCAv during both control hypoxia and augmented FICO~2~ in normoxia ([Fig. 1C](#pone-0081130-g001){ref-type="fig"}). However, in contrast to the findings by Subudhi et al., [@pone.0081130-Subudhi2], we observed no further increase in MCAv with augmented FICO~2~ in hypoxia. The discrepancies between these findings could potentially be accounted for by the differences in the experimental setup and/or the level of hypercapnia achieved. In the study by Subudhi et al., [@pone.0081130-Subudhi2], PETCO~2~ was clamped at 50 mmHg throughout exercise, while our subjects\' PETCO~2~ were on average, ∼46 and ∼43 mmHg in normoxia and hypoxia respectively ([Fig. 1A](#pone-0081130-g001){ref-type="fig"}), reaching ∼53 and ∼47 mmHg at maximal exercise intensity ([Fig. 2A & 2B](#pone-0081130-g002){ref-type="fig"}). Meanwhile, using our Altitrainer setup, Siebenmann et al., [@pone.0081130-Siebenmann1] were able to increase MCAv during incremental exercise in moderate hypobaric hypoxia (3,454 m) by clamping PETCO~2~ at 40 mmHg in altitude sojourners. We deem it unlikely that differences in experimental setup are sufficient to account for these discrepant findings between the three studies. An alternative explanation is the potential influence of (partial) altitude acclimatization [@pone.0081130-Staab1]. Subudhi et al., [@pone.0081130-Subudhi2] examined the effect of CO~2~ clamping on competitive cyclists living and training at 1,650 m, therefore already acclimatized to exercise at moderate altitude. Likewise, the subjects in Siebenmann et al., [@pone.0081130-Siebenmann1] had spent one night at altitude. In contrast, the subjects in our study had not been exposed to altitude \>1000 m in the 2 months prior the study. Since acclimatization to altitude augments the cerebrovascular responsiveness to CO~2~ [@pone.0081130-Fan2], the increase in CBF observed by both Subudhi et al., [@pone.0081130-Subudhi2] and Siebenmann et al., [@pone.0081130-Siebenmann1] may therefore be due to a partial state of acclimatization to altitude.

![Effect of hypoxia and augmented FICO~2~ on mean respiratory, cerebrovascular, metabolic and cardiac variables and perceived effort of exertion during incremental cycling to exhaustion.\
Values expressed as mean ± SD. \* different from control (P\<0.05); † different from normoxia (P\<0.05); § trend for a difference (P\<0.10).](pone.0081130.g001){#pone-0081130-g001}

![Effect of hypoxia and augmented FICO~2~ on group respiratory, cerebrovascular variables and peripheral O~2~ saturation during incremental cycling to exhaustion.\
Left panels: group data in normoxia (mean ± SD); right panels: group data in hypoxia. Note: these graphs are only intended for visualizing the changes in physiological parameters during incremental cycling. Statistical analyses were carried out using the average variable during the exercise session (see [Figure 1](#pone-0081130-g001){ref-type="fig"}).](pone.0081130.g002){#pone-0081130-g002}

Cerebral O~2~ delivery and performance in hypoxia {#s4a}
-------------------------------------------------

Contrary to our first hypothesis, augmenting FICO~2~ during incremental exercise in normobaric hypoxia failed to improve aerobic exercise capacity. This finding corroborates recent findings in milder (hypobaric) hypoxic conditions [@pone.0081130-Subudhi2], [@pone.0081130-Siebenmann1]. The relationship between cerebral deoxygenation and exercise performance in normoxia [@pone.0081130-Seifert1] and hypoxia [@pone.0081130-Smith1]--[@pone.0081130-Goodall1] is therefore unlikely to be causally related to the loss of aerobic capacity in hypoxia. However, it cannot be excluded that augmenting FICO~2~ introduces limits that overrule the potential benefit of improved cerebral CO~2~ delivery. Siebenmann et al., [@pone.0081130-Siebenmann1] argued that inspired CO~2~ may exacerbate the metabolic acidosis associated with heavy exercise, shifting the oxyhemoglobin curve rightward, decreasing SaO~2~, thus limiting peak O~2~. In agreement, our results show a reduction in average heart rate in hypoxia ([Fig. 1G](#pone-0081130-g001){ref-type="fig"}) and a tendency for maximal exercise capacity to be actually impaired with augmented FICO~2~ (P = 0.091), as also reported elsewhere [@pone.0081130-Subudhi2], [@pone.0081130-Siebenmann1]. In agreement with Subudhi et al., [@pone.0081130-Subudhi2], we found the participants\' RPE to increase more rapidly with augmented FICO~2~ in normoxia ([Fig. 3G](#pone-0081130-g003){ref-type="fig"}), in parallel with the increase in ventilation ([Fig. 2C](#pone-0081130-g002){ref-type="fig"}). But contrary to Siebenmann et al., [@pone.0081130-Siebenmann1], our findings of higher SpO~2~ with augmented FICO~2~ in hypoxia throughout submaximal exercise intensities, and similar SpO~2~ at exhaustion ([Fig. 2H](#pone-0081130-g002){ref-type="fig"}), which exclude a right-ward shift in the oxyhemoglobin curve would have limited pulmonary oxygen uptake.

![Effect of hypoxia and augmented FICO~2~ on metabolic variables, heart rate, and perceived effort of exertion during incremental cycling to exhaustion.\
Left panels: group data in normoxia (mean ± SD); right panels: group data in hypoxia. Note: these graphs are only intended for visualizing the changes in physiological parameters during incremental cycling. Statistical analyses were carried out using the average variable during the exercise session (see [Figure 1](#pone-0081130-g001){ref-type="fig"}).](pone.0081130.g003){#pone-0081130-g003}

Limits to cerebral vasodilation {#s4b}
-------------------------------

While controversy remains, there is a large body of literature suggesting that nitric oxide, prostanoids and C-natriuretic peptide are involved in the cerebral vasodilatory responses to both hypercapnia and hypoxia through a number of intermediate interacting/co-activating pathways [@pone.0081130-Ainslie1]. We speculate that if one chemical stimulus, such as hypoxia, is of sufficient magnitude to exhaust the cerebral vessels\' capacity to vasodilate, thereby reaching maximal diameter of the vessels, then any additional stimuli would have no further effect on cerebrovascular resistance. Our data indicate that the CBF response to hypoxia is enhanced during exercise compared to rest, while adding CO~2~ to the inspired gas during exercise only elevates CBF during normoxia, but not during severe hypoxia ([Fig. 1C](#pone-0081130-g001){ref-type="fig"}). The 'normal' cerebrovascular reactivity to hypercapnia thus appears to be abolished during exercise in severe hypoxia ([Fig. 2F](#pone-0081130-g002){ref-type="fig"}). In support, we found no difference between the MCAv values between augmented FICO~2~ in normoxia and control hypoxia (P = 0.193). Such exhaustion of the cerebral vessels\' vasodilatory reserve would account for the lack of change in MCAv with augmented FICO~2~ during sub-maximal exercise in hypoxia. Mardimae et al., [@pone.0081130-Mardimae1] demonstrated a synergistic role of CO~2~ and hypoxia on the control of CBF at rest whereas our results would favor a negative effect, whereby the presence of severe hypoxia appears to attenuate the effect of hypercapnia on the cerebral vessels. Our data indicates that during incremental exercise in hypoxia, the role of hypercapnia in the regulation of cerebrovascular tone appears to be diminished -- at least in an unacclimatized population. However, we cannot exclude the possibility that there might be regional differences in the cerebral vessel response to hypoxia and hypercapnia, which could display additive or synergistic interactions between the two chemical stimuli. Furthermore, the effect of combining hypoxia and hypercapnia on cerebral metabolism is unknown. Given the limited literature on this topic, further studies on the effect of hypoxia, hypercapnia and acclimatization status on regulation of cerebrovascular tone and therefore cerebral O~2~ delivery during exercise in altitude is certainly warranted.

Chemoreception and exercise hyperpnea {#s4c}
-------------------------------------

The regulation of exercise hyperpnea has been extensively studied during the past 100 years \[see [@pone.0081130-Mateika1]--[@pone.0081130-Poon1] for reviews\]. Nevertheless, the role of chemoreception in the regulation of exercise hyperpnea, especially during heavy exercise remains controversial [@pone.0081130-Babb3], [@pone.0081130-Hopker1]. To date, only a handful of studies have examined the effect of chemoreceptor stimulation with CO~2~ alone [@pone.0081130-Olin1], [@pone.0081130-Fan1], [@pone.0081130-Babb2], [@pone.0081130-Babb4], [@pone.0081130-Clark1] or the combined effects of hypoxia and hypercapnia on exercise hyperpnea [@pone.0081130-Asmussen1]. Our second hypothesis stated that increasing PETCO~2~ and decreasing PETO~2~ would stimulate the chemoreceptors and lead to an increase in the ventilatory response to exercise. We found that hypoxia and augmented FICO~2~ had an additive effect on exercise hyperpnea below the RC threshold ([Fig. 4C](#pone-0081130-g004){ref-type="fig"}). As reported before in conditions of normoxia [@pone.0081130-Fan1], adding CO~2~ to the inspirate during normoxic and hypoxic conditions indeed increased ventilation at rest and during incremental exercise ([Table 1](#pone-0081130-t001){ref-type="table"} & [Fig. 5](#pone-0081130-g005){ref-type="fig"}). However, at higher intensities, above the RC threshold, this effect progressively lessened, in spite of a progressive increase in PETCO~2~, again similarly to what we found before in normoxia [@pone.0081130-Fan1]. Hypoxia *per se* augmented the ventilatory response to incremental exercise (the rate of ventilation increase during exercise) below the RC threshold, while augmented FICO~2~ attenuated this rate of increase ([Fig. 5](#pone-0081130-g005){ref-type="fig"}). Hypoxia shifted the RC threshold to lower exercise intensities, which is further exacerbated with augmented FICO~2~ ([Fig. 4A](#pone-0081130-g004){ref-type="fig"} & [5B](#pone-0081130-g005){ref-type="fig"}). No differences were observed in the slope of the ventilatory response to exercise above the RC threshold between any of the conditions ([Fig. 4D](#pone-0081130-g004){ref-type="fig"}). We thus confirm that below the RC threshold both hypoxia and hypercapnia can modulate the rate of ventilatory response to increasing exercise, presumably through chemoreceptor stimulation. However, once above the ventilatory compensation threshold, the chemoreflex ventilatory responses are blunted.

![Effect of hypoxia and augmented FICO~2~ on respiratory compensation threshold and ventilatory response to exercise during incremental cycling to exhaustion.\
Values expressed as mean ± SD. \* different from control (P\<0.05); † different from normoxia (P\<0.05); § trend for a difference (P\<0.10).](pone.0081130.g004){#pone-0081130-g004}

![Effect of hypoxia and augmented FICO~2~ on respiratory compensation threshold and ventilatory response to exercise during incremental cycling to exhaustion.\
A: group data in normoxia (mean ± SD); B: group data in hypoxia. \* different from control (P\<0.05); † different from normoxia (P\<0.05); § trend for a difference (P\<0.10).](pone.0081130.g005){#pone-0081130-g005}
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###### Effect of hypoxia and augmented FICO~2~ on resting respiratory, cerebrovascular and cardiovascular variables.

![](pone.0081130.t001){#pone-0081130-t001-1}

                         Normoxia   Hypoxia                                                                                                                      
  --------------------- ---------- --------- ----- ------ --- -------------------------------------- ------ --- ------------------------------------- ------ --- -----------------------------------------------------------------------
  **~Ventilatory~**                                                                                                                                              
  PETCO~2~ (mmHg)           36         ±       3     43    ±    2[\*](#nt102){ref-type="table-fn"}     32    ±    2[†](#nt103){ref-type="table-fn"}     40    ±    2[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  PETO~2~ (mmHg)            96         ±       4    116    ±    4[\*](#nt102){ref-type="table-fn"}     45    ±    3[†](#nt103){ref-type="table-fn"}     55    ±    3[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  E (L/min)                11.6        ±      1.8   24.1   ±   5.1[\*](#nt102){ref-type="table-fn"}   16.5   ±   2.4[†](#nt103){ref-type="table-fn"}   28.5   ±   5.5[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}
  O~2~ (ml/min)            350         ±      64    394    ±                    63                    346    ±                   91                    375    ±                                    75
  CO~2~ (ml/min)           320         ±      67    285    ±                    51                    444    ±   85[†](#nt103){ref-type="table-fn"}    282    ±                    66[\*](#nt102){ref-type="table-fn"}
  **Cerebrovascular**                                                                                                                                            
  MCAv (cm/s)               54         ±      10     67    ±   10[\*](#nt102){ref-type="table-fn"}     54    ±                   12                     66    ±                    16[\*](#nt102){ref-type="table-fn"}
  **Cardiovascular**                                                                                                                                             
  HR (b/min)                70         ±       7     74    ±                    13                     88    ±                    7                     84    ±                    7[\*](#nt102){ref-type="table-fn"}
  MAP (mmHg)                90         ±       7     99    ±                    11                     90    ±                   14                    100    ±                                     9
  SpO~2~ (%)                97         ±       1     98    ±                    1                      85    ±    5[†](#nt103){ref-type="table-fn"}     91    ±    3[\*](#nt102){ref-type="table-fn"} [†](#nt103){ref-type="table-fn"}

Values are mean ± SD.

\*different from control (P\<0.05);

different from normoxia (P\<0.05).

N = 10 for all variables except VO~2~ and VCO~2~ where N = 9.

Siebenmann et al., [@pone.0081130-Siebenmann1] suggested that, during heavy exercise in hypoxia, the hyperventilation-induced hypocapnia might attenuate ventilatory drive and limit the ventilatory response to exercise. They further speculated that the mechanical constraints associated with high intensity exercise ventilation may be reduced in hypobaric hypoxia, while at the same time hypocapnia would be more pronounced, so that a blunting effect of hypocapnia on E would persist or become more pronounced. Since we performed our experiments in normobaric conditions our results were not influenced by differences in air density, neglecting the small increases in N~2~ and CO~2~ in exchange of O~2~ in our inspirates. In our young and active, but not-athletic subjects, mechanical limitation would seem unlikely since maximal ventilation only reached ∼70% of estimated MVV with augmented FICO~2~ both in normoxia and hypoxia.

Methodological considerations {#s4d}
-----------------------------

Although the present study provided the opportunity to examine the effects of augmented FICO~2~ on CBF response and exercise capacity during incremental exercise in hypoxia, an important limitation of the present study, as of many other studies, is the assumption that MCAv represents global CBF changes. Sato et al., [@pone.0081130-Sato1] recently found that blood flow in the middle cerebral and internal carotid arteries declined from moderate (60% O~2~max) to high intensity exercise (80% O~2~max), whilst blood flow in the vertebral artery continued to increase at the higher intensities. This led Vogiatzis et al., [@pone.0081130-Vogiatzis1] to suggest that vertebral artery blood flow may compensate for reductions of MCA blood flow during near-maximal or maximal exercise. However, since the relative contribution of the internal carotid artery (and therefore MCA) to global CBF remains relatively unchanged (∼65%) at high intensity exercise [@pone.0081130-Sato1], we contend that MCAv is a reasonable index of changes in global CBF during heavy exercise. Further consideration when interpreting our MCAv data is the potential influence of hypoxia and hypercapnia on the MCA diameter. The cross-sectional area of the MCA was shown to remain relatively unchanged within a wide range of changes in PETCO~2~ [@pone.0081130-Bradac1]--[@pone.0081130-Serrador1] and during exposure to hypoxia similar to that used in the present study (5,300 m) [@pone.0081130-Wilson1]. However, since no studies have examined the effect of exercise on MCA diameter, nor when superimposed with hypoxia and hypercapnia, we cannot exclude the possibility MCA diameter might have increased in our study, leading to an underestimation of the effect of augmented FICO~2~ or hypoxia on CBF. In addition, since we did not measure cerebral tissue oxygenation, it is possible that we were unable to elevated cerebral O~2~ delivery with our experimental setup. However, in the present study, SpO~2~ was elevated with augmented FICO~2~ throughout exercise in hypoxia ([Fig. 1D](#pone-0081130-g001){ref-type="fig"}), while MCAv was comparable between the control and augmented FICO~2~ conditions ([Fig. 1C](#pone-0081130-g001){ref-type="fig"}). We would therefore expect cerebral O~2~ delivery, which is the product of arterial O~2~ saturation and CBF, to be elevated with augmented FICO~2~ in hypoxia, leading to increased cerebral tissue oxygenation.

Another limitation of the present study is that we increased end-tidal rather than arterial PCO~2~ during exercise, while it is known that the end-tidal-arterial PCO~2~ gradient [@pone.0081130-Robbins1] varies with exercise [@pone.0081130-Jones1], [@pone.0081130-Liu1]. Using our setup, Siebenmann et al., [@pone.0081130-Siebenmann1] were successful in clamping both end-tidal and arterial PCO~2~ at around 40 mmHg during incremental exercise in hypoxia. Therefore, we believe it is likely that we were able to sufficiently elevate PaCO~2~.

Finally, in the present study, we used a linear ramp protocol to assess the effect of augmented FICO~2~ on the ventilatory response during incremental exercise. It should be acknowledged that during incremental exercise, lower peak O~2~ and work output is obtained during ramp vs. step protocols [@pone.0081130-Zuniga1], while the steepness of the ramp (i.e., 10 W/min, 30 W/min or 50 W/min), pedaling frequency and baseline workload can influence the onset of ventilatory threshold, peak O~2~ and the O~2~-workload relationship [@pone.0081130-Weston1], [@pone.0081130-Boone1]. Therefore, our conclusions on the ventilatory response to exercise should only be limited to the specific ramp protocol (30 W/min) used in the present study. Furthermore, since all the aforementioned studies [@pone.0081130-Subudhi2], [@pone.0081130-Siebenmann1] only looked at aerobic capacity using incremental exercise tests until voluntary exhaustion, which have limited ecological validity [@pone.0081130-Currell1], it remains to be investigated if increasing MCAv by augmenting FICO~2~ during steady-state sub-maximal endurance exercise such as a time trial could improve performance in hypoxia, as time trial exercise provide a more accurate simulation of physiological responses during actual competitions [@pone.0081130-Foster1] and correlate well with actual race performance [@pone.0081130-Palmer1].

Conclusions {#s5}
===========

We report two novel findings. Firstly, augmenting FICO~2~ increases cerebral blood flow during sub-maximal exercise in normoxia, but not in hypoxia. This finding indicates that the 'normal' cerebrovascular response to hypercapnia is impaired during exercise in hypoxia, possibly due to an exhaustion of cerebral vasodilatory reserve. Secondly, above the ventilatory recruitment threshold, both in normoxia and hypoxia, the chemoreflex ventilatory responses are blunted.
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